Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pulmatrix Inc (PULM)

Pulmatrix Inc (PULM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,378
  • Shares Outstanding, K 3,652
  • Annual Sales, $ 7,300 K
  • Annual Income, $ -14,120 K
  • 60-Month Beta 0.92
  • Price/Sales 1.01
  • Price/Cash Flow N/A
  • Price/Book 0.41
Trade PULM with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.56 +33.32%
on 03/28/24
2.19 -5.02%
on 04/16/24
+0.41 (+24.55%)
since 03/25/24
3-Month
1.55 +34.19%
on 03/19/24
2.19 -5.02%
on 04/16/24
+0.26 (+14.58%)
since 01/25/24
52-Week
1.55 +34.19%
on 03/19/24
3.14 -33.76%
on 05/03/23
-0.75 (-26.61%)
since 04/25/23

Most Recent Stories

More News
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 2.08 (+2.97%)
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious...

PULM : 2.08 (+2.97%)
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.08 (+2.97%)
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 2.08 (+2.97%)
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.08 (+2.97%)
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.08 (+2.97%)
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.08 (+2.97%)
Pulmatrix Supports World Asthma Day 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.08 (+2.97%)
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.08 (+2.97%)
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease...

PULM : 2.08 (+2.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease...

See More

Key Turning Points

3rd Resistance Point 2.22
2nd Resistance Point 2.16
1st Resistance Point 2.12
Last Price 2.08
1st Support Level 2.02
2nd Support Level 1.96
3rd Support Level 1.92

See More

52-Week High 3.14
Fibonacci 61.8% 2.53
Fibonacci 50% 2.35
Fibonacci 38.2% 2.16
Last Price 2.08
52-Week Low 1.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar